Enveric Biosciences, Inc.
ENVB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 93.5% and free cash flow fell 29.3%, each against the same quarter a year earlier.
Follow ENVB
Enveric Biosciences, Inc. (ENVB) Altman Z-score
Enveric Biosciences, Inc.'s Altman Z-score for fiscal 2018 cannot be worked out: shares outstanding not reported.
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2017 | 11488289.90 | (13,261,620.17) |
| FY2016 | 24749910.07 | (18,962,670.16) |
| FY2015 | 43712580.23 | — |
How fiscal 2018’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.16) | — | −0.19 | |
| Retained earnings / total assets | (1.16) | — | −1.63 | |
| EBIT / total assets | (0.24) | — | −0.80 | |
| Market value of equity / total liabilities | — | — | n/a | — |
| Sales / total assets | 1.45 | — | 1.45 | |
| Altman Z-score | n/a — shares outstanding not reported | — | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −5.84 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IMNN Imunon, Inc. compare | −12.5× |
| EVGN Evogene Ltd. compare | −20.5× |
| LEXX Lexaria Bioscience Corp. compare | −23.9× |
| TRAW Traws Pharma, Inc. compare | −89.5× |
| TCRT Alaunos Therapeutics, Inc. compare | −436× |
| ENVB Enveric Biosciences, Inc. | — |
| NRSN NeuroSense Therapeutics Ltd. compare | — |
| ALZN Alzamend Neuro, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets